KEYNOTE-042 and the role for single agent pembrolizumab in patients with PD-L1 tumor proportion score 1-49%-MedSci.cn

KEYNOTE-042 and the role for single agent pembrolizumab in patients with PD-L1 tumor proportion score 1-49%

Morgensztern, D

Morgensztern, D (reprint author), Washington Univ, Sch Med, Div Med Oncol, St Louis, MO 63110 USA.

JOURNAL OF THORACIC DISEASE, 2019; 11 (): S1963

科室
- - 订阅+
  - 更多科室
工具
服务